Weight Loss

Novo Nordisk A/S (NYSE:NVO) has reportedly slashed list prices for its obesity drug Wegovy by about 50% in parts of China, signaling a defensive move ahead of rising generic competition. Citing local print media, Bloomberg noted on Monday that prices for the two highest Wegovy doses were reduced to...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S' (NYSE:NVO) Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events. Wegovy pill became the...

Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (semaglutide) control study arm. “...

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Track LLY stock here. GLP-1 Demand Is Becoming Structural The obesity and...

Novo Nordisk A/S (NYSE:NVO) on Thursday submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema. The application covers CagriSema for use with a reduced-calorie diet and increased physical activity to treat obesity or overweight in the...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are...

Novo Nordisk A/S (NYSE:NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro. Novo Nordisk’s stock was significantly hit when the company shared headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program, investigating once-weekly subcutaneous...

On Friday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Novo Nordisk A/S’ (NYSE:NVO) higher dose of Wegovy (semaglutide 7.2 mg). Novo Nordisk has also applied to the EMA for a single-dose device to deliver Wegovy 7.2...

Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s (NYSE:LLY) experimental oral weight-loss treatment, orforglipron. The initiative is part of the National Priority Voucher program,...

Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the Phase 3 TRIUMPH-4 trial evaluating the two highest investigational doses of retatrutide. Eli Lilly shares are advancing steadily. Why is LLY stock trading higher? Retatrutide is a GIP, GLP-1, and glucagon triple hormone...

Eli Lilly and Co. (NYSE: LLY) on Tuesday today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The synthetic medicine active pharmaceutical ingredient (API) facility is the third of four new U.S. sites Eli Lilly plans to announce, will...

Wave Life Sciences Ltd. (NASDAQ:WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for obesity. A single 240 mg dose of WVE-007 led...

Fractyl Health Inc. (NASDAQ:GUTS) on Tuesday revealed 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in obese individuals who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1...

Eli Lilly and Co. (NYSE:LLY) on Monday announced that Zepbound (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company's digital healthcare platform. Zepbound is a prescription drug for weight loss. The update builds on Lilly's ongoing efforts to lower out-...

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7. The company is evolving beyond neurology and that is not reflected in market capitalization. Analyst Brian Abrahams on Monday wrote that Neumora...